Trillium Asset Management LLC Has $6.42 Million Stake in Omnicell, Inc. (NASDAQ:OMCL)

Trillium Asset Management LLC grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 12.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,115 shares of the company's stock after purchasing an additional 16,040 shares during the period. Trillium Asset Management LLC owned approximately 0.31% of Omnicell worth $6,416,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Royce & Associates LP boosted its holdings in shares of Omnicell by 4.4% during the fourth quarter. Royce & Associates LP now owns 19,417 shares of the company's stock worth $864,000 after purchasing an additional 820 shares during the period. Swiss National Bank grew its stake in shares of Omnicell by 0.9% in the 4th quarter. Swiss National Bank now owns 90,500 shares of the company's stock valued at $4,029,000 after buying an additional 800 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Omnicell by 46.1% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock worth $19,130,000 after buying an additional 135,650 shares during the last quarter. AlphaQuest LLC grew its position in Omnicell by 307.8% in the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock worth $159,000 after acquiring an additional 2,699 shares in the last quarter. Finally, Amundi raised its holdings in shares of Omnicell by 56.0% during the 4th quarter. Amundi now owns 39,309 shares of the company's stock valued at $1,694,000 after purchasing an additional 14,115 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Remove Ads

Omnicell Trading Up 3.5 %

Shares of OMCL traded up $1.20 during trading hours on Monday, hitting $35.14. 380,919 shares of the stock traded hands, compared to its average volume of 497,546. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.75. The firm has a market capitalization of $1.64 billion, a PE ratio of 130.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The business has a fifty day moving average of $39.77 and a 200-day moving average of $42.90.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on OMCL shares. Benchmark reissued a "buy" rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Wells Fargo & Company decreased their price target on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. decreased their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday. Finally, StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Omnicell currently has a consensus rating of "Hold" and a consensus target price of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.